Robins J M, Finkelstein D M
Harvard School of Public Health, Boston, Massachusetts 02115, USA.
Biometrics. 2000 Sep;56(3):779-88. doi: 10.1111/j.0006-341x.2000.00779.x.
AIDS Clinical Trial Group (ACTG) randomized trial 021 compared the effect of bactrim versus aerosolized pentamidine (AP) as prophylaxis therapy for pneumocystis pneumonia (PCP) in AIDS patients. Although patients randomized to the bactrim arm experienced a significant delay in time to PCP, the survival experience in the two arms was not significantly different (p = .32). In this paper, we present evidence that bactrim therapy improves survival but that the standard intent-to-treat comparison failed to detect this survival advantage because a large fraction of the subjects either crossed over to the other therapy or stopped therapy altogether. We obtain our evidence of a beneficial bactrim effect on survival by artificially regarding the subjects as dependently censored at the first time the subject either stops or switches therapy; we then analyze the data with the inverse probability of censoring weighted Kaplan-Meier and Cox partial likelihood estimators of Robins (1993, Proceedings of the Biopharmaceutical Section, American Statistical Association, pp. 24-33) that adjust for dependent censoring by utilizing data collected on time-dependent prognostic factors.
艾滋病临床试验组(ACTG)的随机试验021比较了复方新诺明与雾化戊烷脒(AP)作为艾滋病患者肺孢子菌肺炎(PCP)预防治疗的效果。尽管随机分配到复方新诺明组的患者出现PCP的时间显著延迟,但两组的生存情况并无显著差异(p = 0.32)。在本文中,我们提供证据表明复方新诺明治疗可提高生存率,但标准的意向性治疗比较未能发现这种生存优势,因为很大一部分受试者要么交叉接受另一种治疗,要么完全停止治疗。我们通过人为地将受试者首次停止或转换治疗时视为依赖删失,从而获得复方新诺明对生存有益影响的证据;然后,我们使用删失加权的逆概率Kaplan-Meier方法以及罗宾斯(1993年,《美国统计协会生物制药分会论文集》,第24 - 33页)的Cox偏似然估计量来分析数据,这些估计量通过利用随时间变化的预后因素所收集的数据来调整依赖删失情况。